Peng R, Zuo S, Li X, Huang Y, Chen S, Zou X
iScience. 2024; 27(2):108834.
PMID: 38303703
PMC: 10830865.
DOI: 10.1016/j.isci.2024.108834.
Sorino C, Mondoni M, Marchetti G, Agati S, Inchingolo R, Mei F
J Clin Med. 2023; 12(22).
PMID: 38002620
PMC: 10672377.
DOI: 10.3390/jcm12227006.
Hu Q, Wang R, Zhang J, Xue Q, Ding B
Cancer Immunol Immunother. 2023; 72(12):4293-4308.
PMID: 37907644
PMC: 10992448.
DOI: 10.1007/s00262-023-03564-7.
Kasai T, Fukushima S
Nanomaterials (Basel). 2023; 13(18).
PMID: 37764628
PMC: 10536709.
DOI: 10.3390/nano13182598.
Pan Z, Li S, Wang Y, Liu H, Gui L, Dong B
Nan Fang Yi Ke Da Xue Xue Bao. 2023; 43(6):906-914.
PMID: 37439162
PMC: 10339299.
DOI: 10.12122/j.issn.1673-4254.2023.06.05.
ATG5 as biomarker for early detection of malignant mesothelioma.
Tomasetti M, Monaco F, Strogovets O, Volpini L, Valentino M, Amati M
BMC Res Notes. 2023; 16(1):61.
PMID: 37095543
PMC: 10127310.
DOI: 10.1186/s13104-023-06330-1.
Assessment of the toxicity and carcinogenicity of double-walled carbon nanotubes in the rat lung after intratracheal instillation: a two-year study.
Saleh D, Luo S, Ahmed O, Alexander D, Alexander W, Gunasekaran S
Part Fibre Toxicol. 2022; 19(1):30.
PMID: 35449069
PMC: 9026941.
DOI: 10.1186/s12989-022-00469-8.
Subcellular localization of HMGB1 in human cholangiocarcinoma: correlation with tumor stage.
Suwannakul N, Midorikawa K, Du C, Qi Y, Zhang J, Xiang B
Discov Oncol. 2022; 12(1):49.
PMID: 35201494
PMC: 8777519.
DOI: 10.1007/s12672-021-00446-1.
Use of an antagonist of HMGB1 in mice affected by malignant mesothelioma: a preliminary ultrasound and optical imaging study.
Venturini M, Mezzapelle R, La Marca S, Perani L, Spinelli A, Crippa L
Eur Radiol Exp. 2022; 6(1):7.
PMID: 35132475
PMC: 8821768.
DOI: 10.1186/s41747-021-00260-y.
Value of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy to treat malignant peritoneal mesothelioma.
Wang T, Li H, Ye B, Zhang D
Am J Transl Res. 2021; 13(9):10712-10720.
PMID: 34650746
PMC: 8506998.
The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma.
Lettieri S, Bortolotto C, Agustoni F, Lococo F, Lancia A, Comoli P
J Clin Med. 2021; 10(5).
PMID: 33802313
PMC: 7959144.
DOI: 10.3390/jcm10051034.
miR-665 is downregulated in glioma and inhibits tumor cell proliferation, migration and invasion by targeting high mobility group box 1.
Shen H, Xu L, You C, Tang H, Wu H, Zhang Y
Oncol Lett. 2021; 21(2):156.
PMID: 33552274
PMC: 7798026.
DOI: 10.3892/ol.2020.12417.
HMGB1, the Next Predictor of Transcatheter Arterial Chemoembolization for Liver Metastasis of Colorectal Cancer?.
Sun Y, Zhang H, Chen Y, Wu C, Zhang J, Xu H
Front Oncol. 2021; 10:572418.
PMID: 33473353
PMC: 7812918.
DOI: 10.3389/fonc.2020.572418.
High mobility group box 1 induces bone pain associated with bone invasion in a mouse model of advanced head and neck cancer.
Nakamura T, Okui T, Hasegawa K, Ryumon S, Ibaragi S, Ono K
Oncol Rep. 2020; 44(6):2547-2558.
PMID: 33125145
PMC: 7640359.
DOI: 10.3892/or.2020.7788.
Cardiopulmonary Bypass Induces Acute Lung Injury via the High-Mobility Group Box 1/Toll-Like Receptor 4 Pathway.
Deng Y, Hou L, Xu Q, Liu Q, Pan S, Gao Y
Dis Markers. 2020; 2020:8854700.
PMID: 33062073
PMC: 7532999.
DOI: 10.1155/2020/8854700.
HMGB1 Promotes the Proliferation and Metastasis of Lung Cancer by Activating the Wnt/β-Catenin Pathway.
Wang X, Zhang S, Shi M, Xu X
Technol Cancer Res Treat. 2020; 19:1533033820948054.
PMID: 32815451
PMC: 7444109.
DOI: 10.1177/1533033820948054.
High Mobility Group Box 1 in Human Cancer.
Rapoport B, Steel H, Theron A, Heyman L, Smit T, Ramdas Y
Cells. 2020; 9(7).
PMID: 32664328
PMC: 7407638.
DOI: 10.3390/cells9071664.
Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge.
Abbott D, Bortolotto C, Benvenuti S, Lancia A, Filippi A, Stella G
Cancers (Basel). 2020; 12(5).
PMID: 32392897
PMC: 7281319.
DOI: 10.3390/cancers12051186.
The association between high mobility group box 1 chromatin protein and mitotic chromosomes in glioma cells.
Jia L, Song H, Fan W, Song Y, Wang G, Li X
Oncol Lett. 2020; 19(1):745-752.
PMID: 31897190
PMC: 6924194.
DOI: 10.3892/ol.2019.11170.